A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Ex Vivo Administration of Mesenchymal Stromal Cells in Kidney Grafts Against Ischemia Reperfusion Injury – Effective Delivery Without Kidney Function Improvement Posttransplant
2020
Transplantation
Original Basic Science-General Background. Mesenchymal stromal cell (MSC) therapy may improve renal function after ischemia-reperfusion injury in transplantation. Ex vivo renal intraarterial administration is a targeted delivery method, avoiding the lung vasculature, a known barrier for cellular therapies. In a randomized and blinded study, we tested the feasibility and effectiveness of MSC therapy in a donation after circulatory death autotransplantation model to improve posttransplant kidney
doi:10.1097/tp.0000000000003429
fatcat:4vb5xbghbrfebeau24afffjsa4